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Abstract: Scaling up voluntary medical male circumci-
sion (VMMC) for HIV prevention is cost saving and creates
fiscal space in the future that otherwise would have been
encumbered by antiretroviral treatment costs. An invest-
ment of US$1,500,000,000 between 2011 and 2015 to
achieve 80% coverage in 13 priority countries in southern
and eastern Africa will result in net savings of
US$16,500,000,000. Strong political leadership, country
ownership, and stakeholder engagement, along with
effective demand creation, community mobilisation, and
human resource deployment, are essential. This collection
of articles on determining the cost and impact of VMMC
for HIV prevention signposts the way forward to scaling
up VMMC service delivery safely and efficiently to reap
individual- and population-level benefits.
Male Circumcision for HIV Prevention
Despite a 22-fold increase since 2001 in the number of people
receiving antiretroviral therapy, two people acquire HIV infection
for every person starting treatment [1]. Scaling up evidence-
informed HIV prevention programs is imperative. In the HIV
prevention toolbox of behavioural, biomedical, and structural
approaches to combine for maximum effect [2], VMMC is an
essential tool in all high HIV prevalence, predominantly
heterosexual epidemic settings. It provides lifelong partial
protection for men against HIV infection [3–6] and reduces their
likelihood of genital ulcers [7,8], syphilis [9], and penile cancer
[10].
Observational data and ecological studies have suggested for
decades that male circumcision provides a level of protection from
HIV infection for men [11]. Three randomised controlled trials
[3–5] conducted in the last decade found a 57% protective effect
against HIV for men who became circumcised [6]. All three trials
were stopped prematurely because it was deemed unethical to
withhold VMMC from men in the control arm waiting to be
circumcised.
Following trial results, the World Health Organization (WHO)
and the Joint United Nations Programme on HIV/AIDS
(UNAIDS) rapidly convened stakeholders in March 2007 to
evaluate the strength of the evidence and to consider the policy
and programmatic implications. The resulting recommendations
addressed the essential components for program implementation
in 13 priority countries (Botswana, Kenya, Lesotho, Malawi,
Mozambique, Namibia, Rwanda, South Africa, Swaziland,
Tanzania, Uganda, Zambia, and Zimbabwe) in eastern and
southern Africa with settings of high HIV prevalence and low
levels of male circumcision [12,13].
Male circumcision is the oldest and most common surgical
procedure. With 30% of men globally and 67% of men in sub-
Saharan Africa circumcised [14], social and cultural factors are the
main determinants of acceptability [6,15–18]. In sub-Saharan
Africa, male circumcision was found to be acceptable to men and
women in non-circumcising communities if readily accessible and
provided safely [18]. Mathematical modelling has shown that
medical male circumcision is highly cost-effective, with costs to
avert one HIV infection ranging from US$150 to US$900 using a
ten-year time horizon, and one new HIV infection averted for
every five to fifteen procedures performed [19].
Given these levels of acceptability, cost, and potential impact,
VMMC provided by well-trained, well-equipped providers in
hygienic settings should be scaled up rapidly in high HIV
prevalence settings to reap both individual- and population-level
benefits. Policy makers and program planners interested in moving
services to scale are faced, however, with decisions about which
populations to prioritise (newborns, adolescents, adults, men at
higher risk of HIV exposure, such as those in serodiscordant
couples), what service delivery models to use (fixed, outreach,
mobile), which human resources to deploy (physicians, clinical
officers, nurses), how to create demand and match supply to it, and
what speed of scale-up is both desirable and feasible.
Policy makers in high HIV prevalence countries will find
valuable information to support rapid scale-up of services in this
collection on the cost and impact of VMMC for HIV prevention.
The articles highlight progress to date, explore challenges to
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forward now, leaders will set their countries on course to achieve
the 50% reduction in sexual transmission of HIV by 2015 that
they signed on to at the United Nations General Assembly in June
2011 [20].
Numbers of Male Circumcisions Needed
How many medical male circumcisions will need to be
performed in the 13 priority countries for maximum impact?
The first step towards answering this question is assessing baseline
prevalence of male circumcision in each country, recognising that
self-reported circumcision status, as Thomas et al. [21] demon-
strate for Lesotho, can be inaccurate. Njeuhmeli et al. [22]
estimate the number of VMMC procedures needed to reach 80%
prevalence using the Decision Makers’ Program Planning Tool
[23] for male circumcision, an interactive tool that incorporates
country-specific demographics, epidemic dynamics, and locally
derived cost estimates. An estimated 20.3 million circumcisions
among men 15–49 years of age are needed to close the gap by
2015. Once eligible uncircumcised men have been reached
through ‘‘catch-up’’ campaigns, annual costs fall because ongoing
programs need only maintain coverage while shifting to long-term
sustainable strategies. These could include systematically offering
the procedure to one cohort per year, such as young men turning
15 years of age or all male newborns.
As Mwandi et al. [24] detail, Kenya is on track, with over 66%
of its target for Nyanza Province met through sustained
government leadership, financial and technical support of
international donors, and a partnership strategy that has engaged
a broad array of stakeholders. Swaziland has reached 13%,
Zambia and Botswana have attained 4%, and Tanzania and
South Africa have met 3% of their respective 2015 80% objectives,
through campaigns that picked up speed in 2010 (see Figure 1).
Efficiently Mobilising Human Resources
Among the impediments to scaling up VMMC services are
concerns about human resources. Curran et al. [25] review the
concepts of task shifting and task sharing and describe approaches
to expanding the health sector workforce through redeployment of
existing personnel and use of expatriate volunteers, drawing on
experiences in Tanzania, Kenya, and Swaziland. Scaling up
VMMC requires a streamlined campaign footing and rapid
mobilisation of human resources to eventually achieve a steady
state that will make fewer demands on the health care system.
Both surgical and non-surgical efficiency gains have significant
impacts on per procedure costs and therefore on the numbers of
medical male circumcisions that can be performed. Significant
efforts are underway to test a number of medical devices that, if
found to be safe, acceptable, and effective, would dramatically
reduce procedure times [26–28] and speed the scale-up.
Determining Costs of Scale-Up
VMMC scale-up planning requires cost estimates for commod-
ity procurement, supply chain management, and disposal of waste
generated by male circumcision programs. Edgil et al. [29]
describe a costing framework for these program components for
Swaziland, emphasising the advantages of a standard kit of the
consumables and dedicated instruments necessary for one male
circumcision procedure [30,31].
VMMC program planning necessitates the design and imple-
mentation of effective demand creation strategies that encourage
men to consider male circumcision for HIV prevention and
actively seek out VMMC services. Timely matching of supply to
demand is critical to avoid men seeking unsafe procedures because
waiting times are too long. Mahler et al. [32] describe how this
challenge was met while ensuring service quality and efficiency in
Iringa, Tanzania. As Bertrand et al. [33] underscore, demand
creation strategies must be tailored to specific country contexts to
determine the most effective mix of mass media, small media,
outreach, and community mobilisation communication approach-
es. Recognising that no standard package applies in all settings,
they propose a seven-step methodology to estimate demand
creation costs for inclusion in country VMMC costing estimates.
The United States President’s Emergency Plan for AIDS Relief
(PEPFAR) (through the US Agency for International Development
Health Policy Initiative) and the UNAIDS supported primary data
collection activities to estimate facility-based unit costs for
VMMC, as currently delivered, in Uganda, Kenya, Zambia,
Zimbabwe, South Africa, and Namibia. These estimates were
revised to include a more comprehensive assessment of cost
components, including waste management, supply chain manage-
ment, training, and overhead costs. Assumptions were made about
future task shifting and task sharing to optimise the volume and
efficiency of services [31]. Unit cost estimates, excluding demand
creation costs, were estimated at US$80.13 per adult VMMC.
Country unit costs were then adjusted to account for differences in
labour costs, and sensitivity analyses assumed a 20% higher and
20% lower unit cost.
Combining unit cost data with the numbers of VMMCs needed
to achieve 80% coverage in all 13 countries results in an estimated
US$1,500,000,000 required between 2011 and 2015. Maintaining
80% coverage in all 13 countries between 2016 and 2025 would
require an additional US$500,000,000. Sensitivity analyses under-
score the importance of minimising costs while ensuring safe, high-
quality procedures accompanied by effective HIV prevention
messages. If unit costs were 20% higher, an additional
US$500,000,000 would be required over the full 2011–2025 period,
while a 20% decrease in unit costs would reduce overall resources
required by US$500,000,000. Given the estimated discounted
individual lifetime cost of antiretroviral therapy of US$7,400,
VMMC is not only cost-effective in these countries—it is cost
saving. Net savings from 2011 to 2015 due to averted treatment and
care costs amount to US$16, 00,000,000. Therefore, an initial
investment now in VMMC, although substantial, will be returned
many fold. It will create fiscal space in the future that otherwise
would have been encumbered by antiretroviral treatment costs.
Estimating the Impact
Just how many infections could be averted by scaling up VMMC
to reach 80% malecircumcision prevalence in allcountries ineastern
and southern Africa in five years and maintaining that coverage
through to 2025? Where would the largest impact be seen? Through
2025, 3.4 million new HIV infections would be averted, as Figure 2
shows, with South Africa alone averting over 1 million new HIV
infections between 2011 and 2025. More than 20% of projected new
HIV infections would be averted in Botswana, Lesotho, Malawi,
Namibia, Rwanda, Swaziland, Uganda, Zambia, and Zimbabwe.
The number of VMMCs needed to avert one HIV infection ranges
from a low of four in Zimbabwe to a high of 44 in Rwanda.
Among the infections averted are those among women who
benefit indirectly from VMMC scale-up. As more men become
circumcised, women are less likely to encounter sexual partners
who have HIV infection. Eventually, even uncircumcised men will
benefit indirectly from VMMC scale-up [19]. Early on, most HIV
infections averted occur among men, but the proportion among
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5Figure 1. Achievement towards target of 80% coverage. This figure illustrates that most countries have had only limited success in bridging
the gap between historical male circumcision levels and the 80% target. The one exception is Kenya, which has achieved more than 66% of its
objective, primarily in Nyanza Province.
doi:10.1371/journal.pmed.1001127.g001
Figure 2. Cumulative number and percentage of HIV infections averted between 2011 and 2025 by scaling up adult VMMC to reach
80% coverage in five years. This figure illustrates the significant impact that achieving 80% VMMC coverage of 15- to 49-year-old men would have
on the epidemics in 13 countries in eastern and southern Africa. South Africa can avert the largest number of HIV infections (over 1 million between
2011 and 2025); Zimbabwe can avert the highest percentage of new HIV infections (almost 42%). More than 20% of new HIV infections would be
averted between 2011 and 2025 in nine countries: Botswana, Lesotho, Malawi, Namibia, Rwanda, Swaziland, Uganda, Zambia, and Zimbabwe. Nyanza
refers to Nyanza Province in Kenya: the data presented are only for Nyanza Province in Kenya, as this is the only province in Kenya with prevalence of
male circumcision lower than 80% and is the province with the highest HIV prevalence compared to the national average.
doi:10.1371/journal.pmed.1001127.g002
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infections averted in the year 2025 are those that would have
occurred among women.
The anticipated impact of scaling up VMMC is directly
proportional to the pace and scale of implementation. Decreasing
VMMC coverage targets from 80% to 50% results in a decline in
the total number of HIV infections averted from 3.4 million to 1.1
million. Reducing the time to achieve 80% coverage from five
years to one year has the opposite effect, increasing the number of
HIV infections averted from 3.4 million to 4.1 million. This
decreases the cost per HIV infection averted and increases total
cost savings due to HIV infections averted. Maximum epidemic
impact accrues the more quickly maximum coverage is achieved.
Determinants of Early Adoption and Sustained
Scale-Up
Some countries need to offer medical male circumcision to
fewer than 500,000 men and could achieve 80% coverage in less
than two years, while those that have to offer circumcision to more
than 2–3 million men will take longer. However, it is not just the
size of the task that will determine whether objectives are met,
impact is realised, and cost savings occur. As Dickson et al. [34]
demonstrate, key barriers and facilitators are influencing the speed
of scale-up. Characteristics of the response to the compelling
scientific evidence of the HIV prevention benefits of VMMC in
each of the 13 countries permit a classification of countries into
four categories: innovators, early adopters, early and late majority,
and laggards. Against a backdrop of varying sociopolitical and
cultural contexts, the key drivers of early adoption and sustained
scale-up are country ownership, explicit political leadership,
engagement of stakeholders, and community mobilisation.
Conclusion
What will it take for the citizens of the 13 priority countries in eastern
and southern Africa to reap the prevention benefits of VMMC?
Domestic funding can be mobilised and international funding accessed
through PEPFAR, the Bill & Melinda Gates Foundation, and the
Global Fund to Fight AIDS, Tuberculosis and Malaria. However, it
will take leadership and visible champions at all levels to mobilise and
deploy this funding for maximum effect. This is precisely the ‘‘decisive,
inclusive, and accountable leadership’’ called for in the United Nations’
2011 political declaration on HIV/AIDS [20]. It will take community
conversations to create new social norms about male circumcision in
previously non-circumcising communities. It will take women speaking
out on the HIV prevention benefits and the desirability of male
circumcision for their sexual partners, brothers, and sons. It will take
tailored communication strategies to create demand for VMCC
services, and it will take program planners who have anticipated
increasing demand and are matching it with supply of safe, acceptable,
and accessible services. It will take continued innovations in medical
device development and testing, along with other efficiency gains, to
decrease procedure times and thereby increase access.
Above all, it will take vision by government leaders who
understand that promoting effective VMMC programming now
will create synergies to more rapidly halt and reverse their
countries’ epidemics. Scaling up VMMC requires considerable
short-term investment of financial and human resources to
accelerate gains toward coverage objectives. Once achieved,
countries will arrive at a sustained and sustainable ‘‘cruising’’
level requiring far fewer resources to maintain 80% coverage. The
challenge before them is to climb over the ‘‘catch-up’’ hump to
reap substantive HIV prevention benefits. The faster that
countries do this, the more rapidly will both direct benefits for
men and indirect benefits for women accrue. Six million people
are on antiretroviral therapy, 9 million more are eligible today,
according to the current WHO recommendations of providing
antiretroviral treatment for patients with CD4 cell counts of ,350
cells/ml [35], and pressure is mounting to offer even more people
treatment for prevention [1,36]. The opportunity costs of not
taking action to scale up VMMC safely and rapidly now to prevent
new HIV infections and create fiscal space are too high to ignore.
This is on our watch—what role is each one of us playing to ensure
that VMMC contributes fully to halting and reversing the HIV
epidemic in eastern and southern Africa?
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